Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30807248 | 1.00 | MAP4K4 (0.39) | MAP4K4HDAC1GPR119NR1H2NR1H3 | |
| SCHEMBL31364497 | 0.94 | MAP4K4 (0.35) | MAP4K4HDAC1GPR119NR1H2NR1H3 | |
| SCHEMBL31364508 | 0.94 | MAP4K4 (0.35) | MAP4K4HDAC1GPR119NR1H2NR1H3 | |
| SCHEMBL30807356 | 0.91 | OGA (0.36) | OGACTSKPIN1KMT2AHRH3 | |
| SCHEMBL30807292 | 0.90 | ABCB1 (0.33) | OGAACKR3PIN1ABCB1KMT2A | |
| SCHEMBL30807239 | 0.87 | ACKR3 (0.41) | OGAACKR3KMT2AHRH3P2RY12 | |
| SCHEMBL30807299 | 0.85 | OGA (0.34) | OGAPIN1KMT2A | |
| SCHEMBL30807291 | 0.84 | OGA (0.31) | OGA | |
| SCHEMBL31364502 | 0.81 | MAP4K4 (0.41) | MAP4K4OGASUV39H2ACKR3PIN1 | |
| SCHEMBL27147177 | 0.81 | CKS1B (0.39) | OGASUV39H2ACKR3ABCB1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062407-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2025-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062407-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX3, PRDX2 | MAP4K4 3590/4885HDAC1 981/4885GPR119 1775/4885 |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | MAP4K4 3663/4885HDAC1 922/4885GPR119 2539/4885 |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | MAP4K4 3685/4885HDAC1 903/4885GPR119 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.